[Adamson feels that drug developers are unreasonably concerned about rare events.] The reality is children tolerate phase I therapy [new agents being tested to find the best dosage and possible side-effects] as well as or better than adults, ... Once the initial studies are done – that is, phase I trials in adults – study should begin in children. |
For many children current therapies are curative. But the price they pay in long-term side effects is far too high. |
Our ability to move ahead has waned. Overcoming the most difficult cancers with higher doses is not likely to succeed anymore. |
There's a desperate need for new approaches, |
There's a desperate need for new approaches. The success in pediatric oncology has been made with drugs that have been around for 30 years. |